BioArctic AB (publ) (BIOA-B.ST)
SEK 166.1
(0.91%)
SEK 166.1
(0.91%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 229.24 Million SEK | 2150.89% |
| 2022 | -11.17 Million SEK | 90.67% |
| 2021 | -119.78 Million SEK | -74.83% |
| 2020 | -68.51 Million SEK | -177.45% |
| 2019 | 88.46 Million SEK | -76.82% |
| 2018 | 381.6 Million SEK | 2417.66% |
| 2017 | 15.15 Million SEK | -73.68% |
| 2016 | 57.58 Million SEK | 1452.02% |
| 2015 | 3.71 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -68.42 Million SEK | -18.87% |
| 2024 Q1 | -57.56 Million SEK | 34.02% |
| 2023 Q1 | 293.85 Million SEK | 607.73% |
| 2023 Q4 | -87.24 Million SEK | -169.82% |
| 2023 Q2 | -102.31 Million SEK | -134.82% |
| 2023 Q3 | 124.95 Million SEK | 222.12% |
| 2023 FY | 229.24 Million SEK | 2150.89% |
| 2022 Q3 | 136.79 Million SEK | 398.43% |
| 2022 FY | -11.17 Million SEK | 90.67% |
| 2022 Q4 | -57.87 Million SEK | -142.31% |
| 2022 Q2 | -45.83 Million SEK | -3.14% |
| 2022 Q1 | -44.44 Million SEK | -134.46% |
| 2021 Q2 | -34.17 Million SEK | -17.5% |
| 2021 Q1 | -29.08 Million SEK | -120.38% |
| 2021 Q4 | -18.95 Million SEK | 49.55% |
| 2021 Q3 | -37.57 Million SEK | -9.93% |
| 2021 FY | -119.78 Million SEK | -74.83% |
| 2020 Q3 | -20.65 Million SEK | 45.97% |
| 2020 Q4 | -13.19 Million SEK | 36.09% |
| 2020 FY | -68.51 Million SEK | -177.45% |
| 2020 Q1 | 3.55 Million SEK | 120.79% |
| 2020 Q2 | -38.22 Million SEK | -1175.46% |
| 2019 FY | 88.46 Million SEK | -76.82% |
| 2019 Q4 | -17.09 Million SEK | -105.21% |
| 2019 Q3 | -8.33 Million SEK | -108.31% |
| 2019 Q2 | 100.26 Million SEK | 635.68% |
| 2019 Q1 | 13.62 Million SEK | -95.93% |
| 2018 FY | 381.6 Million SEK | 2417.66% |
| 2018 Q2 | 5.12 Million SEK | -66.79% |
| 2018 Q4 | 335.2 Million SEK | 1196.43% |
| 2018 Q1 | 15.41 Million SEK | 30.26% |
| 2018 Q3 | 25.85 Million SEK | 404.9% |
| 2017 Q3 | -116 Thousand SEK | -105.0% |
| 2017 FY | 15.15 Million SEK | -73.68% |
| 2017 Q4 | 11.83 Million SEK | 10304.31% |
| 2017 Q2 | 2.32 Million SEK | 107.97% |
| 2017 Q1 | 1.11 Million SEK | -98.51% |
| 2016 Q1 | -4.81 Million SEK | 0.0% |
| 2016 FY | 57.58 Million SEK | 1452.02% |
| 2016 Q4 | 74.96 Million SEK | 1066.29% |
| 2016 Q3 | -7.75 Million SEK | 10.75% |
| 2016 Q2 | -8.69 Million SEK | -80.58% |
| 2015 FY | 3.71 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | 1491.074% |
| Amniotics AB (publ) | -30.87 Million SEK | 842.627% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 1887.099% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 149.176% |
| Genovis AB (publ.) | 61.5 Million SEK | -272.763% |
| LIDDS AB (publ) | -40.2 Million SEK | 670.186% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | -1783.877% |
| OncoZenge AB (publ) | -15.9 Million SEK | 1541.636% |
| Saniona AB (publ) | -95.81 Million SEK | 339.275% |
| Simris Alg AB (publ) | -37.3 Million SEK | 714.526% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 173.727% |
| AcouSort AB (publ) | -17.08 Million SEK | 1441.5% |
| Active Biotech AB (publ) | -45.8 Million SEK | 600.544% |
| Camurus AB (publ) | 431.44 Million SEK | 46.864% |
| Cantargia AB (publ) | -280.02 Million SEK | 181.867% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 1186.952% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 302.297% |
| Mendus AB (publ) | -101.61 Million SEK | 325.597% |
| Kancera AB (publ) | -64.88 Million SEK | 453.294% |
| Karolinska Development AB (publ) | 5.38 Million SEK | -4156.387% |
| Lipum AB (publ) | -37.17 Million SEK | 716.625% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 1990.246% |
| NextCell Pharma AB | -41.95 Million SEK | 646.354% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 159.059% |
| Xintela AB (publ) | -54.08 Million SEK | 523.884% |
| Ziccum AB (publ) | -21.41 Million SEK | 1170.657% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 1498.032% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 1380.935% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 718.405% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 227.597% |
| CombiGene AB (publ) | -35.66 Million SEK | 742.777% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 250.971% |
| Intervacc AB (publ) | -102.85 Million SEK | 322.892% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 192.221% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 52439.954% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 1487.454% |
| Corline Biomedical AB | -1.8 Million SEK | 12772.692% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 228.908% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 503.458% |
| Aptahem AB (publ) | -11.11 Million SEK | 2162.915% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 286.278% |
| Fluicell AB (publ) | -26.55 Million SEK | 963.331% |
| Biovica International AB (publ) | -124.82 Million SEK | 283.659% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 642.948% |
| Abliva AB (publ) | -95.5 Million SEK | 340.029% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 170.128% |
| 2cureX AB (publ) | -32.51 Million SEK | 804.991% |
| I-Tech AB | 20.2 Million SEK | -1034.728% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 127.563% |
| Cyxone AB (publ) | -22.98 Million SEK | 1097.212% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 350.817% |
| Biosergen AB | -27.03 Million SEK | 947.908% |
| Nanologica AB (publ) | -75.15 Million SEK | 405.027% |
| SynAct Pharma AB | -215.81 Million SEK | 206.227% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 620.382% |
| BioInvent International AB (publ) | -330.3 Million SEK | 169.405% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 1065.788% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 192.027% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 2408.648% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 309.766% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 2063.084% |